Genmab — November 2019
-
HexaBody-DR5/DR5 - A Phase I/II clinical trial in solid tumors was on a brief partial clinical hold for discussions with the
U.S. FDA. This partial hold has been lifted and the dose escalation part of the trial is ongoing. - *Initial data now anticipated in 2020. A status update will be available in 2019 -
Og vi runder 500 besøgende i chatten på en gang lige om lidt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind